Alteplase Is Effective Up to 4.5 Hours After Onset of Ischemic Stroke But earlier is better.


On the basis of reports published in September 2008 from two large international studies, professional stroke organizations extended the recommended time between symptom onset and administration of alteplase from 3 to 4.5 hours (JW Emerg Med Sep 24 2008 and JW Emerg Med Sep 15 2008). To assess implementation of the wider treatment window and its effects, investigators analyzed data for nearly 24,000 patients who were included in one of the study’s stroke registry from 2002 to 2010.

Overall, 2376 patients received alteplase between 3 and 4.5 hours after symptom onset; the proportion of patients who were treated within this window was three times higher in the last quarter of 2009 than in the first quarter of 2008. Rates of poor outcomes were low: 7.1% of patients treated within 3 hours and 7.4% of those treated at 3 to 4.5 hours had symptomatic intracerebral hemorrhage and 12.3% and 12.0%, respectively, died within 3 months. However, in analyses adjusted for confounding variables, patients treated at 3 to 4.5 hours had significantly higher rates of symptomatic intracerebral hemorrhage (1 extra hemorrhage for every 200 patients) and 3-month mortality (1 extra death for every 333 patients), as well as significantly worse functional outcomes (odds ratio for functional independence, 0.84). Median time from admission to treatment was 65 minutes before and after the reports. The authors conclude that the extended treatment window was implemented rapidly with no overall increase in admission-to-treatment time and that although risk from alteplase was greater when administered at 3 to 4.5 hours, treatment was still beneficial.

Comment: Although the U.S. FDA has not yet approved use of alteplase beyond 3 and up to 4.5 hours after onset of ischemic stroke symptoms, this evidence supports a wider treatment window and professional organizations recommend it. Nevertheless, time is brain, and eligible patients should be treated as soon as possible.


Published in Journal Watch Emergency Medicine August 27, 2010

i phone : funny pics


iGotaBigAssPocket Concept

A Comparative Chart Between Two Tablets

A Comparative Chart Between Two Tablets

Apple iPad Advertising: 35% Superlative Garbage

Apple iPad Advertising: 35% Superlative Garbage

iPad Future

iPad Future

iLame

iLame

iPad Nano

iPad Nano

iPad Vs. Blu-Tack

iPad Vs. Blu-Tack

iPhad

iPhad

iPad With Wings

iPad With Wings

iPad Tampon

iPad Tampon

iPad Always

iPad Always

iPad – Expensive Bulky iPhone

iPad - Expensive Bulky iPhone

iPad – iSpade

iPad - iSpade

Multitasking iPad

Multitasking iPad

The Real iPad

The Real iPad

The New iPad

The New iPad

iPod Touch 2G + Mushroom = iPad

iPod Touch 2G + Mushroom = iPad

iMaxi

iMaxi

Get Used

Get Used

<br>

Massive solar storm to hit Earth in 2012 with ‘force of 100m bombs


Astronomers are predicting that a massive solar storm, much bigger in potential than the one that caused spectacular light shows on Earth earlier this month, is to strike our planet in 2012 with a force of 100 million hydrogen bombs.

Several US media outlets have reported that NASA was warning the massive flare this month was just a precursor to a massive solar storm building that had the potential to wipe out the entire planet’s power grid.

Despite its rebuttal, NASA’s been watching out for this storm since 2006 and reports from the US this week claim the storms could hit on that most Hollywood of disaster dates – 2012.

Similar storms back in 1859 and 1921 caused worldwide chaos, wiping out telegraph wires on a massive scale. The 2012 storm has the potential to be even more disruptive.

“The general consensus among general astronomers (and certainly solar astronomers) is that this coming Solar maximum (2012 but possibly later into 2013) will be the most violent in 100 years,” News.com.au quoted astronomy lecturer and columnist Dave Reneke as saying.

“A bold statement and one taken seriously by those it will affect most, namely airline companies, communications companies and anyone working with modern GPS systems.

“They can even trip circuit breakers and knock out orbiting satellites, as has already been done this year,” added Reneke.

No one really knows what effect the 2012-2013 Solar Max will have on today’s digital-reliant society.

Dr Richard Fisher, director of NASA’s Heliophysics division, told Reneke the super storm would hit like “a bolt of lightning”, causing catastrophic consequences for the world’s health, emergency services and national security unless precautions are taken.

NASA said that a recent report by the National Academy of Sciences found that if a similar storm occurred today, it could cause “1 to 2 trillion dollars in damages to society’s high-tech infrastructure and require four to 10 years for complete recovery”.

The reason for the concern comes as the sun enters a phase known as Solar Cycle 24.

Most experts agree, although those who put the date of Solar Max in 2012 are getting the most press.

They claim satellites will be aged by 50 years, rendering GPS even more useless than ever, and the blast will have the equivalent energy of 100 million hydrogen bombs.

“We know it is coming but we don’t know how bad it is going to be,” Fisher told Reneke.

“Systems will just not work. The flares change the magnetic field on the Earth and it’s rapid, just like a lightning bolt. That’s the solar effect,” he added.

The mind’s eye: How the brain sorts out what you see


Can you tell a snake from a pretzel? Some can’t – and their experiences are revealing how the brain builds up a coherent picture of the world

AFTER her minor stroke, BP started to feel as if her eyes were playing tricks on her. TV shows became confusing: in one film, she was surprised to see a character reel as if punched by an invisible man. Sometimes BP would miss seeing things that were right before her eyes, causing her to bump into furniture or people.

BP’s stroke had damaged a key part of her visual system, giving rise to a rare disorder called simultanagnosia. This meant that she often saw just one object at a time. When looking at her place setting on the dinner table, for example, BP might see just a spoon, with everything else a blur (Brain, vol 114, p 1523).

BP’s problems are just one example of a group of disorders known collectively as visual agnosias, usually caused by some kind of brain damage. Another form results in people having trouble recognising and naming objects, as experienced by the agnosic immortalised in the title of Oliver Sacks’s 1985 best-seller The Man Who Mistook His Wife for a Hat.

Agnosias have become particularly interesting to neuroscientists in the past decade or so, as advances in brain scanning techniques have allowed them to close in on what’s going on in the brain. This gives researchers a unique opportunity to work out how the brain normally makes sense of the world. “Humans are naturally so good at this, it’s difficult to see our inner workings,” says Marlene Behrmann, a psychologist who studies vision at Carnegie Mellon University in Pittsburgh, Pennsylvania. Cases like BP’s are even shedding light on how our unconscious informs our conscious mind. “Agnosias allow us to adopt a reverse-engineering approach and infer how [the brain] would normally work,” says Behrmann.

Although we may not give it much thought, our ability to perceive our world visually is no mean feat; the most sophisticated robots in the world cannot yet match it. From a splash of photons falling on the retina – a 3-centimetre-wide patch of light-sensitive cells – we can discern complex scenes comprising multiple items, some near, some far, some well lit, some shaded, and with many objects partly obscured by others.

The information from the photons hitting a particular spot on the retina is restricted to their wavelength (which we perceive as colour), and their number (which determines brightness). Turning that data into meaningful mental images is a tough challenge, because so many variables are involved. For example, the number of photons bouncing off an object depends both on the brightness of the light source and on how pale or dark the object is. “The information that the visual system receives is very impoverished,” says Behrmann.

It is in the visual cortex, located at the back of the brain, where much of the processing goes on. When items obscure each other, the brain must work out where one thing ends and another begins, and take a stab at their underlying shapes. It must recognise things from different perspectives: consider the image of a chair viewed from the side compared with from above. Then there’s the challenge of recognising novel objects – a futuristic new chair, for example. “Somehow, almost magically, we derive a meaningful interpretation of complex scenes very rapidly,” says Behrmann. “How we do this is the million-dollar question in vision research.”

So how does the brain work its magic? In the early 20th century, European psychologists used simple experiments on people with normal vision to glean some basic rules that they called the “gestalt principles”. For example, the brain groups two elements in an image together if they look similar, having the same colour, shape or size, for example. And if not all of an object is visible, we mentally fill in the gaps – that’s the “closure principle” (see “Constructing reality”).

The gestalt principles can only go part of the way to describing visual perception, though. They cover how we separate the different objects in a scene, but they cannot explain how we know what those objects are. How, for example, do we know that a teacup is a teacup whether we see it from above or from the side, in light or in shadow?

It’s here that people with visual agnosias come in handy. Behrmann had previously studied people with integrative agnosia, who have difficulty recognising and naming complex objects as a whole, and instead seem to pay unusual attention to their individual features. One person, for example, mistook a picture of a harmonica for a computer keyboard, presumably thinking the row of air-holes in the mouthpiece were computer keys (Journal of Experimental Psychology: Human Perception and Performance, vol 29, p 19). Others have mistaken a picture of an octopus for a spider, and a pretzel for a snake.

Type 2 Diabetes May Have Link to Alzheimer’s


Study Shows Insulin Resistance May Raise Risk of Brain Plaques Associated With Alzheimer’s

Aug. 25, 2010 — People with insulin resistance or type 2 diabetes may be at increased risk for developing telltale brain plaques that are closely linked to Alzheimer’s disease, a study shows.

The new findings, which appear in the Aug. 25 issue of Neurology, may give more evidence of the connection between diabetes and Alzheimer’s disease.

In insulin resistance, the hormone insulin, produced by the pancreas, becomes less effective in lowering blood sugar.  People with insulin resistance are at risk for developing type 2 diabetes.

“Type 2 diabetes and Alzheimer’s disease are two epidemics growing at alarming levels around the world,” says study researcher Kensuke Sasaki, MD, PhD, with Kyushu University in Fukuoka, Japan, in a news release. “With the rising obesity rates and the fact that obesity is related to the rise in type 2 diabetes, these results are very concerning.”

Checking for Signs of Alzheimer’s

In the new study, 135 Japanese men and women underwent diabetes screening tests in 1988 and were followed for up to 15 years for signs of Alzheimer’s disease. Overall, 16% showed signs of clinical Alzheimer’s disease before they died; 65% of people in the study also showed evidence of plaques in their autopsied brains after death.

People who had abnormal results on their blood sugar tests were more likely to have plaques in their brain, the study shows. This relationship was more pronounced among people who also had a form of the ApoE gene that’s been linked to a higher risk of developing Alzheimer’s disease.

There was no link between insulin resistance and type 2 diabetes and risk for developing brain tangles, another brain abnormality seen with Alzheimer’s disease, the study shows.

“Further studies are needed to determine if insulin resistance is a cause of the development of these plaques,” Sasaki says. If it is,”it’s possible that by controlling or preventing diabetes, we might also be helping to prevent Alzheimer’s disease.”

The new study “supports the hypothesis that insulin resistance and type 2 diabetes is causally related to a higher risk of dementia including Alzheimer’s disease,” writes Jose A. Luchsinger, MD, MPH, in an accompanying editorial.

More studies are needed to figure out precisely how the conditions are connected, he writes.

“This is urgent considering that over half of the U.S. population in the age group most at risk for cognitive impairment has prediabetes or type 2 diabetes,” he writes.

Some current trials are looking at how available insulin-sensitizing drugs affect cognitive impairment.

Prophylactic Use of an Intra-Aortic Balloon Pump


Findings from a randomized study show no benefit in patients at high risk for complications of percutaneous coronary intervention.

Intra-aortic balloon pumps (IABPs) are commonly used to reduce the likelihood of complications in stable high-risk patients undergoing percutaneous coronary intervention (PCI). Investigators for the randomized controlled Balloon Pump–Assisted Coronary Intervention Study evaluated this practice in 301 patients (mean age, 71; 80% men) with left ventricular (LV) ejection fractions of ≤30% and a large amount of myocardium at risk. The investigators excluded patients who fulfill American College of Cardiology/American Heart Association Class I and II recommendations for IABP use: cardiogenic shock, acute myocardial infarction (AMI) within 48 hours before scheduled PCI, or complications of AMI requiring circulatory support. The primary endpoint was the composite of death, AMI, stroke, or further revascularization before hospital discharge.

Twelve percent of patients assigned to no planned IABP underwent rescue IABP insertion. A primary endpoint occurred in 15% of the IABP group and in 16% of the no-planned–IABP group. Three deaths occurred in the IABP group compared with one death in the no-planned–IABP group. MI occurred in about 13% of each group. Two strokes occurred in the IABP group and none in the no-planned–IABP group. Predefined procedural complications (primarily hypotension) were less frequent in the IABP group than in the no-planned–IABP group (1% vs. 11%). However, bleeding was more common in the IABP group (19% vs. 11%), as were access-site complications (3% vs. 0%).

Comment: This trial failed to demonstrate a benefit of elective IABP use in stable high-risk patients undergoing PCI. The results are not definitive; importantly, patients with a Class I or II indication for the device were excluded, and the guideline recommendation for hemodynamic support in these highest-risk patients remains unchallenged. Nonetheless, these findings not only call into question the merits of routine IABP placement in patients with severe LV dysfunction and extensive coronary disease, they also illustrate the importance of testing such “common-sense” strategies in clinical trials.

Published in Journal Watch Cardiology August 25, 2010

Is Drinking Wine a Key to Antiaging?


The latest antiaging weapon is not an injection or a wonder cream, and it doesn’t involve any nipping or tucking either.

It’s a glass of red wine a day for women and two for men, according to Richard A. Baxter, MD, a plastic surgeon in Seattle and the author of Age Gets Better with Wine. Baxter gave a talk on wine and beauty at the annual meeting of the American Society for Aesthetic Plastic Surgery in Washington, D.C.

WebMD sat down with him to discuss exactly how age gets better with wine.

Here’s what he had to say:

Wine and beauty, really?

There is quite a lot of data on the wine and beauty connection. I was surprised at how extensive the data is on wine as an antiaging intervention.

What is it about wine that can help us age and look better?

The mechanism is the antioxidants in red wine. Antioxidants sop up damaging free radicals that play a role in aging and age-related diseases. There is a much higher concentration of antioxidants called polyphenols, including resveratrol, in wine compared to grape juice. In wine, the skin and seeds are part of the fermenting process, but both are removed when making grape juice.

I think stress has something to do with it, too. It is difficult to sort out how much of the benefits are from the chemical properties of wine vs. the types of behaviors that wine drinkers tend to have such as less stress in their lives. Wine is part of the Mediterranean diet, which is also rich in fresh fruits and vegetables, whole grains, nuts and seeds, legumes, seafood, yogurt, and olive oil. This diet is more of a lifestyle that includes drinking wine with dinner. Studies show that the Mediterranean diet is associated with longer, healthier lives.

Any caveats?

Drinking a glass of red wine a day is the single most important thing that you can do other than nonsmoking, from an antiaging point of view, but you can have too much of a good thing. Drinking more than recommended can have the opposite effect on your appearance and health.

What is your wine prescription for WebMD readers?

A glass a day and your skin will glow. As antiaging advice, this is as good as it gets.

Specifically, what benefits can a person expect if they follow your advice?

You will look better, your skin will glow, and you will live five years longer than a teetotaler. There are also good studies that show people who drink red wine on a regular basis have fewer actinic keratoses [precancerous skin lesions]. You will have a significantly lower risk of Alzheimer’s disease, cancer, diabetes, and all of the things that go along with aging. People assume that drinking would decrease brainpower as you get old, but the most amazing thing is that regular wine drinkers have an 80% lower risk of developing Alzheimer’s disease.

What about people who can’t consume alcohol?

People who can’t drink wine should such look to other whole foods with polyphenols and antioxidants, like pomegranates and blueberries. Or go for dark chocolate. It does a lot of the same things as wine. Both dark chocolate and red wine have been shown to protect the skin from sun damage.

Will winemakers put plastic surgeons out of business?

No. It’s an adjunctive thing.

There are some supplements out there that say they have the ingredients — namely resveratrol — that make red wine so healthy. Do they work?

The data is really minimal in terms of the effectiveness of resveratrol supplements. The jury is out about whether you get same benefits in a pill that you get with a glass of red wine.

What about skin creams with resveratrol?

This will be the next big thing in skin care. Stay tuned.

Are any wines better than others?

White wines do not have as many antioxidants as red wines. In terms of reds, it has more to do with the way the grapes are grown than the varieties of wine. Oregon pinot noirs tend to have higher levels of polyphenols and European wines tend to have more polyphenols than American wines, in general.

What type of wine do you drink?

I like all red wines, but I am really partial to Australian shiraz.

Recurrent Headaches in Teens Linked to Unhealthy Lifestyle



Adolescents who smoke, are overweight, or are inactive face increased risk for recurrent headaches, according to a cross-sectional study in Neurology.

Nearly 6000 teenagers in Norway completed headache interviews and lifestyle questionnaires and underwent clinical examinations. After adjustment for confounders, smoking conferred a 50% increased risk for recurrent headache (migraine, tension-type, or nonclassifiable); overweight, a 40% increased risk; and physical inactivity, a 20% increased risk. The more unhealthy lifestyle factors a teen had, the greater the risk.

Editorialists note that given its design, the study could not determine whether smoking, overweight, and inactivity are headache risk factors, exacerbating factors, or trigger factors. Still, they conclude that the report “sets the stage for lifestyle interventions” for headache disorders in adolescents.

Fish Oil Improves Metabolic Syndrome


Healthy Fats Improve Cholesterol and Triglyceride Levels in Metabolic Syndrome, Study Finds
fish_oil_metabolic_syndrome_3.jpg

Aug. 18, 2010 — A diet rich in omega-3 fish oil or healthy monounsaturated fats found in oils such as olive and canola may be beneficial for people with metabolic syndrome.

Metabolic syndrome is a cluster of risk factors known to increase risk for heart attack and diabetes. Features of metabolic syndrome include high blood pressure, insulin resistance, high cholesterol levels, and abdominal fat. The new findings appear in the September issue of the Journal of Nutrition.

In the study, 117 people with metabolic syndrome were placed on one of four special diets for 12 weeks:

  • A diet high in saturated fat
  • A diet high in monounsaturated fat
  • A diet low in fat and high in complex carbs such as whole grains, fruits, and vegetables
  • A low-fat diet high in complex carbs that was supplemented with omega-3 fatty acids

All of the diets contained similar amounts of calories.

Participants’ blood was tested before and after a meal at the beginning and the end of the study. All the participants showed similar levels of blood cholesterol and blood fats called triglycerides before the study began. After the 12-week study period, however, people who ate diets rich in monounsaturated fat or low-fat, high complex carbs and omega-3 fatty acids had lower triglycerides than their counterparts who were placed on the other two diets.

Study participants whose diets were low in fat and high in complex carbs, a diet sometimes used for weight loss, displayed spikes in cholesterol and triglycerides after their meal. The addition of omega-3 fatty acids, such as found in fish oil, however, seemed to mitigate these effects, the study showed. Fish oil has been shown to reduce triglycerides and improve other cardiovascular risk factors.

Now, the researchers write, “it would be interesting to extend out studies beyond 12 weeks to confirm the longer-term effects of dietary fat interventions on cardiovascular risk factors in metabolic syndrome.”

Fish oil may reduce breast cancer risk


Researchers in the Public Health Sciences Division found regular use of fish oil supplements, which contain high levels of the omega-3 fatty acids EPA and DHA, is associated with a 32 percent reduction in breast cancer risk. The findings—the first to demonstrate such a link—were published in the July issue of the journal Cancer Epidemiology, Biomarkers & Prevention.

The research, led by Dr. Emily White and funded by the National Cancer Institute, adds to the growing evidence that fish oil supplements may play a role in preventing chronic disease.

The study asked 35,016 postmenopausal women who did not have a history of breast cancer to complete a 24-page questionnaire about their use of nonvitamin, nonmineral “specialty” supplements.

After six years of follow-up, 880 cases of breast cancer were identified using the Surveillance, Epidemiology and End Results registry. The reduction in risk appeared to be restricted to invasive ductal breast cancer, the most common type of the disease.

The use of other specialty supplements, many of which are commonly taken by women to treat symptoms of menopause, was not associated with breast cancer risk.

Studies of dietary intake of fish or omega-3 fatty acids have not been consistent.

“It may be that the amount of omega-3 fatty acids in fish oil supplements are higher than most people would typically get from their diet,” said White, who is also a professor and associate dean of the University of Washington’s School of Public Health.

White cautioned against gleaning any recommendations from the results of one study.

“Without confirming studies specifically addressing this, we should not draw any conclusions about a causal relationship,” she said.

Co-authors include Drs. Theodore Brasky, Johanna Lampe and John Potter, all of PHS, and former Center researcher Dr. Ruth Patterson, now at University of California, San Diego.